X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/08/2909601/37568/en/Merus-Announces-First-Patient-Dosed-in-Phase-2-Trial-of-Petosemtamab-in-2L-CRC.html
https://www.globenewswire.com/news-release/2024/07/01/2906655/37568/en/Merus-Appoints-Fabian-Zohren-M-D-Ph-D-as-Chief-Medical-Officer.html
https://www.globenewswire.com/news-release/2024/06/03/2892524/37568/en/Merus-MCLA-129-Demonstrates-Promising-Single-Agent-Efficiency-in-METex14-NSCLC-in-Poster-Presentation-at-the-2024-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/06/02/2891858/37568/en/Merus-Presents-Interim-Data-on-MCLA-145-Monotherapy-and-in-Combination-with-Pembrolizumab-at-the-2024-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/30/2890383/37568/en/Merus-Announces-Pricing-of-Upsized-Public-Offering-of-Common-Shares.html
https://www.globenewswire.com/news-release/2024/05/29/2889802/37568/en/Merus-to-Participate-in-a-Fireside-Chat-at-the-Jefferies-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/28/2888880/37568/en/Merus-Petosemtamab-in-Combination-with-Pembrolizumab-Interim-Data-Demonstrates-Robust-Response-Rate-and-Favorable-Safety-Profile-in-1L-r-m-HNSCC.html
https://www.globenewswire.com/news-release/2024/05/28/2889404/37568/en/Merus-N-V-Announces-Proposed-Public-Offering-of-Common-Shares.html
https://www.globenewswire.com/news-release/2024/05/23/2887679/37568/en/Merus-Announces-Publication-of-Abstracts-for-Presentation-at-the-2024-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/05/23/2887678/37568/en/Merus-Announces-Publication-of-an-Abstract-on-Petosemtamab-with-Pembrolizumab-as-1L-treatment-of-r-m-HNSCC-at-the-2024-ASCO-Annual-Meeting.html
Market Place
Share 
